v3.26.1
Note 3 - Balance Sheet Details - Summary of Accrued Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Notes To Financial Statements [Abstract]    
Accrued accounts payable $ 173 $ 163
Accrued clinical trial expenses 806 801
Accrued chemistry, manufacturing and controls ("CMC") expenses 833 543
Accrued preclinical and translational science expenses 992 188
Accrued director stipends 64 59
Accrued other 268 433
Accrued Liabilities, current, Total $ 3,136 $ 2,187